---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-028386"
form_type: "8-K"
ticker: "ASBP"
cik: "0001847345"
company_name: "Aspire Biopharma Holdings, Inc."
filed_at: "2026-06-12T14:26:16+00:00"
generated_at: "2026-06-12T14:27:08.678246+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aspire Biopharma signs $30M cash deal for auto supplier DCS with >$200M revenue

## Summary
- DCS generated >$200M revenue, >$22M Adjusted EBITDA, >$17M net income in FY2025 (unaudited).
- Purchase price $30M cash; no new equity financing expected; closing targeted Q3 2026.
- DCS operates 11 global facilities, holds 310+ patents, serves 150+ vehicle platforms and blue-chip OEMs.
- Existing DCS CEO Hans Vorstenbosch continues; leadership bolstered by Lakewood & Company with 200+ years experience.
- Acquisition transforms Aspire into diversified high-revenue enterprise while advancing drug delivery technology.

## SEC filing metadata
- accession: 0001493152-26-028386
- form_type: 8-K
- ticker: ASBP
- cik: 0001847345
- company_name: Aspire Biopharma Holdings, Inc.
- filed_at: 2026-06-12T14:26:16+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315226028386/0001493152-26-028386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315226028386/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-028386
- JSON: https://secwatch.observer/filing/0001493152-26-028386.json
- Plain text: https://secwatch.observer/filing/0001493152-26-028386.txt

## Key facts
- Material Agreements
  Aspire Biopharma Holdings, Inc. entered into Purchase Agreement with FireFish TopCo, LLC valued at Purchase price $30,000,000 plus $800,000 deferred revenue credit, minus tax and debt adjustments (effective 2026-06-10).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: FireFish TopCo, LLC
  - Value: Purchase price $30,000,000 plus $800,000 deferred revenue credit, minus tax and debt adjustments
  - Effective: 2026-06-10
  source text: On June 10, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with FireFish TopCo, LLC (the “Seller”, and, collectively with its Subsidiaries listed in Annex A of the Purchase Agreement, “Sellers”), pursuant to which (i) the Seller agreed to sell, and cause the applicable Sellers to sell, and the Company agreed to purchase or cause certain of its Affiliates to purchase, all of the equity interests in certain of Seller’s subsidiaries set forth in Annex C of the Purchase Agreement (the aforementioned equity interests, collectively, the ‘Transferred Equity Interests”, and such subsidiaries, “Transferred Entities”), free and clear of all Liens, other than the Permitted Liens and in accordance with the applicable Local Transfer Documents and (ii) the Seller agreed to sell, and cause the applicable Sellers to sell, and the Company agreed to purchase, or cause certain of its affiliates to purchase, all of the assets of the other
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315226028386/0001493152-26-028386-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.